Güneş Ömer, Kanık-Yüksek Saliha, Kayalı-Akyol Aylin, Akyol Özhan, Güney Ahmet Yasin, Üçkardeş Fatih, Yahşi Aysun, Özen Seval, Erat Tuğba, Gülhan Belgin, Bayhan Gülsüm İclal, Özkaya-Parlakay Aslınur
Department of Pediatric Infectious Diseases, Ankara City Hospital, Ankara, Turkey.
Department of Pediatrics, Ankara City Hospital, Ankara, Turkey.
Expert Rev Anti Infect Ther. 2025 Jul;23(7):491-498. doi: 10.1080/14787210.2025.2493075. Epub 2025 Apr 16.
This study aims to evaluate the risk factors, clinical features, and clinical outcomes among pediatric hospitalized patients receiving treatment for bacteremia and compare the effects of antibiotics used in the treatment on clinical outcomes.
This single-center retrospective study included patients aged between 1 month and 18 years who received treatment for Staphylococcus aureus bacteremia (SAB) betweenSeptember 2019 and September 2022.
SAB was detected in 95 pediatric patients. In MRSA bacteremias, no difference in clinical outcomes was found between patients receiving vancomycin or teicoplanin. In MSSA bacteremias, the recurrence rate of SAB was 0% in the penicillin group and 23.5% in the cephalosporin group. The median duration of bacteremia-related hospital stay (10 vs. 14 days), and the median duration of bacteremia (2 vs. 3 days) were shorter in the ampicillin-sulbactam group than in the piperacillin-tazobactam group ( = 0.016, and = 0.050, respectively).
Teicoplanin was found to have similar clinical outcomes to vancomycin in treating MRSA bacteremia. In addition, ampicillin sulbactam was found to have better clinical outcomes than other antibiotics in treating MSSA bacteremia. Teicoplanin and ampicillin sulbactam may be considered as a choice in the treatment of pediatric SAB.
本研究旨在评估接受菌血症治疗的儿科住院患者的危险因素、临床特征和临床结局，并比较治疗中使用的抗生素对临床结局的影响。
这项单中心回顾性研究纳入了2019年9月至2022年9月期间接受金黄色葡萄球菌菌血症（SAB）治疗的1个月至18岁患者。
95例儿科患者检测出SAB。在耐甲氧西林金黄色葡萄球菌菌血症中，接受万古霉素或替考拉宁治疗的患者临床结局无差异。在甲氧西林敏感金黄色葡萄球菌菌血症中，青霉素组SAB复发率为0%，头孢菌素组为23.5%。氨苄西林-舒巴坦组菌血症相关住院时间中位数（10天对14天）和菌血症持续时间中位数（2天对3天）均短于哌拉西林-他唑巴坦组（分别为P = 0.016和P = 0.050）。
发现替考拉宁在治疗耐甲氧西林金黄色葡萄球菌菌血症方面临床结局与万古霉素相似。此外，发现氨苄西林舒巴坦在治疗甲氧西林敏感金黄色葡萄球菌菌血症方面临床结局优于其他抗生素。替考拉宁和氨苄西林舒巴坦可被视为儿科SAB治疗的选择。
